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Abstract
Heparanase is an endo-β-glucuronidase capable of cleaving heparan sulfate (HS), an activity implicated in tumor
metastasis. Heparanase expression is upregulated in primary human tumors, correlating with reduced post oper-
ative survival and elevated microvessel density. An ELISA method was used to quantify heparanase in urine from
282 individuals. Urine was collected from healthy volunteers (n = 41), patients diagnosed with noncancerous path-
ologic disorders (n = 90), and bladder cancer patients (n = 92). Fifty-nine bladder carcinoma patients after trans-
urethral resection (TUR) with no evidence of disease (NED) were also included. Heparanase levels were significantly
elevated in urine from bladder cancer patients compared with healthy controls (P < .001) and with noncancerous
urinary disorders (P < .05). Heparanase elevation strongly correlated with tumor grade (P < .001) and stage (P =
.027). An optimal cutoff value of 154 pg/ml was determined. Of 199 individuals enrolled (59 patients after TUR and 24
patients with recurring disease were excluded), 65 had heparanase levels above 154 pg/ml. Only 3 of 65 (4.6%) were
healthy individuals. In contrast, 52.3% (34 of 65) of individuals with heparanase levels above 154 pg/ml were bladder
cancer patients. The results indicate that urine heparanase levels are elevated during bladder cancer progression,
suggesting that the ELISA method may be applied for bladder cancer diagnosis.
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Introduction
Bladder carcinoma is the primary malignancy of the urinary tract
system with nearly 60,000 new cases and 13,000 deaths annually
in the United States [1]. Disease mortality rate has not been signif-
icantly changed during the past decade [1,2]. Surgical resection
remains the primary and most effective treatment for carcinoma
in situ (CIS; accounts for 80% of all new cases), although recurrence
rates are high, and patients are required to undergo periodic cysto-
scopic examination as frequently as once every 3 months [3]. The
prospective for metastatic bladder cancer (20%) remains poor. Treat-
ment for refractory superficial tumors or muscle-invasive tumors is
radical cystectomy with urinary diversion. Neoadjuvant chemother-
apy, with or without adjuvant chemotherapy, has also shown promis-
ing results in preventing disease progression and tumor recurrence
in patients with adverse clinical or pathologic features [4]. Diagnosis
of the disease is usually preceded by hematuria and cytologic evalu-
ation, although sensitivity is relatively low. Additional diagnostic
markers include bladder tumor antigen, nuclear matrix protein
(NMP)-22, telomerase, fluorescence in situ hybridization, and
others, yet these are mostly applied for posttreatment surveillance
rather than for diagnosis [3,4]. Thus, better understating of the
biologic nature of the disease is required for the establishment of
new molecular markers for early diagnosis and more efficient treat-
ment modalities.
Abbreviations: CIS, carcinoma in situ; ECM, extracellular matrix; ELISA, enzyme-
linked immunosorbent assay; HS, heparan sulfate; HSPG, heparan sulfate proteoglycan;
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Heparanase is an endo-β-glucuronidase, which cleaves heparan
sulfate (HS) side chains of heparan sulfate proteoglycans (HSPGs)
in a distinct manner [5], an activity that is strongly implicated in cell
dissemination associated with tumor metastasis, inflammation, and
angiogenesis [5–7]. Cleavage of HS, a major constituent of the extra-
cellular matrix (ECM) and basement membranes, is considered an
important step for breaking down the ECM barrier and penetrating
the blood vessel basement membrane required for tumor cell metas-
tasis [8]. This notion gained further support by employing siRNA
and ribosome technologies, clearly depicting heparanase-mediated
HS cleavage and ECM remodeling as critical requisites for inflam-
mation, angiogenesis, and metastatic spread [9–11]. More recently,
heparanase upregulation has been documented in a large number
of primary human carcinomas [12,13]. In many cases, heparanase
upregulation correlated with reduced postoperative survival rates,
increased lymph node and distant metastasis, tumors bigger in size,
and higher microvessel density, collectively providing a strong clinical
support for the prometastatic and proangiogenic nature of the
enzyme and positioning heparanase as an attractive target for the
development of anticancer drugs [14–18]. In addition, HS side
chains can bind a variety of biologic mediators such as growth fac-
tors, enzymes, cytokines and chemokines [19], thus forming a readily
available reservoir that can be liberated on local or systemic cues,
including heparanase availability [20–22]. Extracellular retention of
heparanase is, therefore, kept tightly regulated [13,23–26]. Hepara-
nase upregulation by primary human carcinomas and the secreted
nature of the protein predict that the enzyme may be found in body
fluids such as plasma and urine, the latter being most relevant for
bladder carcinoma. We have recently developed a sensitive ELISA
method capable of determination and quantification of heparanase
and demonstrated that heparanase levels are elevated in the urine
and plasma of cancer patients [27]. Moreover, we have found de-
creased heparanase levels in the plasma of pediatric cancer patients
following anticancer treatment [28]. Here, we used the recently es-
tablished ELISA method to determine heparanase levels in urine
samples collected from a large number of bladder cancer patients
in comparison with heparanase levels in urine collected from patients
diagnosed with noncancerous pathologic disorders and from healthy
volunteers. We provide evidence that heparanase levels are elevated
three- to four-fold in the urine of bladder carcinoma patients, corre-
lating with tumor grade and stage. Moreover, high levels of hepara-
nase were found in the urine of patients with active disease compared
with patients with no evidence of disease (NED) following trans-
urethral resection (TUR), suggesting that heparanase originates pri-
marily from the tumor mass. An optimal cutoff value of 154 pg/ml
was extracted from a receiver operating characteristic (ROC) curve,
and heparanase diagnostic potential was revealed. Of 199 individuals
enrolled, 65 had heparanase levels above 154 pg/ml of which only 3
(4.6%) were healthy individuals. In striking contrast, 52.3% (34 of
65) of the individuals with heparanase levels above 154 pg/ml were
bladder cancer patients, suggesting that the ELISA method may be
applied for bladder cancer diagnosis.
Materials and Methods
Experimental Design
A total of 282 individuals were enrolled in this study and included
healthy control participants (group I, n = 41), patients diagnosed
with noncancerous symptoms such as hematuria, irritative voiding
symptoms, urinary tract infection (UTI), and urinary stones (group
II, n = 90), and patients with primary and recurrent bladder car-
cinoma (group III, n = 92). A group of 59 patients with a history
of superficial bladder carcinomas who were under surveillance
after TUR and who had NED at the time of sample collection
was also included (group IV). All patients in groups II and III, except
those with urolithiasis and UTI, underwent cystoscopy. Tumors
were graded according to the World Health Organization grading
system and were staged according to the TNM classification system
[29]. The study protocol was approved by the Hadassah Hospital
Institutional Review Board. Informed consent was obtained from
every patient.
Urine samples were collected from each patient before cystoscopy,
centrifuged (1500g for 10 minutes) to remove cells and cell debris,
and the supernatant was kept at −20°C until analysis. All patients
were diagnosed at the Oncology and Urology Departments of the
Hadassah-Hebrew University Medical Center, Jerusalem [30].
Heparanase ELISA
Urinary heparanase was analyzed by heparanase ELISA method,
essentially as described [27,28]. Briefly, wells of microtiter plates were
coated (18 hours at 4°C) with 2 μg/ml of anti–heparanase 1E1
monoclonal antibody in 50 μl of coating buffer (0.05 M Na2CO3,
0.05 M NaHCO3, pH 9.6) and were then blocked with 1% BSA in
PBS for 1 hour at 37°C. Samples (200 μl) were loaded in duplicates
and incubated for 2 hours at room temperature, followed by the addi-
tion of 100 μl of anti–heparanase polyclonal antibody 1453 (1 μg/ml)
for an additional 2 hours at room temperature. Horseradish peroxidase–
conjugated goat anti–rabbit IgG (1:20,000) in blocking buffer was
added (1 hour at room temperature), and the reaction was visualized
by the addition of 50 μl of chromogenic substrate (tetramethylben-
zidine) for 30 minutes. The reaction was stopped with 100 μl of
H2SO4, and absorbance at 450 nm was measured with reduction
at 630 nm using an ELISA plate reader. Plates were washed five times
with a washing buffer (PBS, pH 7.4, containing 0.1% (v/v) Tween
20) after each step. As a reference for quantification, a standard curve
was established by a serial dilution of recombinant single-chain
(GS3) active heparanase ranging from 187 pg/ml to 5 ng/ml [27,28].
Statistical Analysis
The distribution of heparanase values in urine was asymmetric;
therefore, nonparametric analyses were applied. Kruskal-Wallis one-
way analysis of variance (ANOVA) was performed to test for overall
homogeneity. Pairs of groups were compared using the Mann-Whitney
test once ANOVA was significant. Correlations between numeri-
cal variables were analyzed by linear nonparametric (Spearman) cor-
relations. Associations between categorical variables were evaluated
with chi-square test. For the analysis of sensitivity–specificity rela-
tion of the assay, an ROC curve was constructed, and the area under
this curve was calculated [30,31]. A P value of < .05 was consid-
ered significant.
Results
Heparanase Elevation in Noncancerous Urinary
Tract Disorders
We evaluated the level of heparanase in urine obtained from
noncancerous and bladder carcinoma patients (Figure 1; Table 1).
The average level of heparanase in the urine of healthy donors was
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61.6 ± 10.5 pg/ml. Patients diagnosed with noncancerous urinary
tract disorders exhibited elevated levels of heparanase (141.7 ±
17.4; Figure 1A), significantly higher than control values (61 ± 10;
P = .05). The variance among the four subgroups of patients with
noncancerous urinary tract conditions (group II; Table 1) was signif-
icant (Kruskal–Wallis test; P = .0291). Paired comparison of the var-
ious groups revealed that heparanase elevation was most prominent
in patients with hematuria (177 ± 37; Table 1) (P < .05), likely due
to the release of heparanase by activated platelets [32], whereas other
noncancerous patients did not significantly differ in their heparanase
levels from the control group.
A substantial increase in heparanase levels was quantified in the
urine of carcinoma patients (210 ± 25; Figure 1A; Table 1), signifi-
cantly higher than noncancerous urinary tract disorders (P < .05).
These results indicate that elevation of urinary heparanase levels is
common in noncancerous and cancerous patients, the latter being
more prominent (Figure 1A).
Urine Heparanase Levels Correlate with Bladder Cancer
Grade and Stage
To further characterize heparanase levels in bladder carcinomas,
the cancer patient group was subdivided into low- (n = 54) and high-
(n = 38) grade tumors, and the respective heparanase levels were
compared to those found in the urine of healthy donors (n = 41)
(Figure 1B; Table 1). A three-fold increase in heparanase levels was
observed in the urine of low-grade bladder cancer patients (192.6 ±
42 pg/ml) and a further increase was measured in urine collected
from high-grade bladder cancer patients (286.5 ± 52.5 pg/ml), dif-
ferences that are statistically highly significant (healthy vs low-grade:
P = .045; healthy vs high-grade: P = .001; low-grade vs high-grade;
P = .0001). Next, we determined urine heparanase levels at distinct
morphologic stages of the disease (Figure 1C; Table 1). Increased
amounts of heparanase were already detected in urine collected
from noninvasive low-grade lesions (pTa, n = 60; 175 ± 24.9 pg/ml)
and was highest in patients with high-grade intraurothelial neoplasia
(CIS, n = 14; 300 ± 69; Figure 1C ), differences that are statistically
highly significant (healthy vs pTa: P = .036; healthy vs CIS: P =
.001; pTa vs CIS: P = .027) (Table 1). Thus, urine levels of heparanase
correlate with bladder cancer grade and stage. Furthermore, patients
with active disease exhibited a four-fold increase in heparanase levels
(210 ± 26), significantly higher than those of patients with NED fol-
lowing TUR (162 ± 31; P = .0175; Table 2). These findings indicate
that urine heparanase originates primarily from the tumor mass.
Receiver Operating Characteristic Curve and
Heparanase Specificity
Because elevated levels of heparanase were detected in urine ob-
tained from cancer and noncancerous patients, an ROC curve was
constructed (Figure 2). The curve delineates a graphical plot of the
sensitivity versus the specificity of the system and is typically used to
determine an optimal cutoff value [31]. The area under the ROC
curve was 0.61 ± 0.04; an optimal cutoff value of 154 pg/ml was
extracted, corresponding to a sensitivity of 51.1%, specificity of
69.7%, and accuracy of 62.8%. The heparanase assay at this cutoff
exhibited sensitivity of 52.7% and 48% for primary and recurrent
bladder cancer, respectively.
Next, we used the cutoff value of 154 pg/ml to examine the sig-
nificance of urine heparanase levels for bladder cancer diagnosis
(Table 3). Of 199 individuals enrolled [excluding patients already
diagnosed (59 patients under surveillance after TUR and 24 patients
with recurrent disease)], 65 had heparanase levels above 154 pg/ml of
Figure 1. Heparanase levels in the urine of bladder cancer and noncancerous patients. (A) Urine was collected from healthy donors (n =
41; group I), patients exhibiting noncancerous pathologic disorders (n = 90; group II), and patients with bladder carcinoma (n = 92;
group III). Heparanase levels were determined using the heparanase ELISA method, as described under the Materials and Methods
section. The variance among the patients in the three groups is highly significant (P < .0001; Kruskal-Wallis test). Paired comparisons
between different groups showed significantly higher urine heparanase values in group III, compared with group II (P < .05) and group I
(P < .001). The difference between group II and group I was also significant (P < .05). Patients with bladder carcinoma were subdivided
according to tumor grade (B) and stage (C) (see Table 1 for more details) and urine heparanase levels were similarly compared to those
determined in healthy control donors.
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which only 3 (4.6%) were healthy individuals, indicating a high de-
gree of specificity of the ELISA assay (Table 3). In striking contrast,
52.3% of the individuals with heparanase levels above 154 pg/ml
were bladder cancer patients (34 of 65), compared with 18.5%
(12 of 65) with hematuria, 12.3% (8 of 65) with irritative voiding
symptoms, and 6.2% (4 of 65) with UTI (Table 3). Thus, urinary
heparanase may be considered as a possible parameter for the diag-
nosis of bladder cancer.
Discussion
Bladder cancer is compliant to biomarker development, because
tumor cells and molecules are shed into the urine and can thus be
diagnosed and monitored. Approximately 75% of bladder tumors are
low-grade and low-stage (i.e., stage Ta), and these tumors rarely prog-
ress [33]. However, approximately 25% of bladder tumors are high-
grade, and early detection of these tumors once still superficial (Ta or
T1) could improve patient’s prognosis [33]. Heparanase upregulation
was observed in essentially all primary human tumors examined, in-
cluding bladder carcinoma [34]. Most often, heparanase induction
correlates with reduced postoperative survival rate, likely due to in-
creased local and distant metastasis [12,35], thus positioning hepa-
ranase as a valid target for the development of anticancer drugs [14–
16,18]. Here, we provide evidence that urine heparanase levels cor-
relate with bladder cancer progression. To the best of our knowledge,
this is the first systematic study examining urinary heparanase and its
diagnostic significance. Importantly, elevated heparanase levels were
detected already in the urine of noninvasive, pTa stage patients, and
further increase in heparanase levels was measured in the urine of CIS
patients (Figure 1C ). Whereas the increase in urinary heparanase at
advanced stages of the disease nicely resembles its elevation at the
protein and mRNA levels [34], noninvasive pTa biopsies rarely
stained for heparanase [36]. Thus, it appears that our ELISA method
is highly sensitive and detects heparanase even at very low levels, sug-
gesting its possible application for primary bladder cancer diagnosis.
To further verify this aspect, we constructed an ROC curve and
determined an optimal cutoff value. The majority of cases (52.3%)
with heparanase levels above 154 pg/ml are bladder cancer patients,
followed by 18.5% of noncancerous hematuria patients (Table 3).
Whereas the latter subgroup is most likely derived from platelet
[32], the urinary heparanase in the cancer patients is primarily tumor-
derived, a notion that is further substantiated by comparing heparanase
levels in the urine of patients with active disease versus NED following
Table 1. Heparanase Levels in the Urine of Patients with Noncancerous Urinary Tract Disorders and Bladder Carcinoma.
Urine Heparanase (pg/ml) Patients with Heparanase Levels above 154 pg/ml
No. of Patients Mean Median SEM No. of Patients (%)
Group I: Healthy control participant 41 61.6 32.5 10.5 3 (7.3)
Group II: Noncancerous disorders 90 141.7 101.1 17.4 28 (30.2)
Hematuria 33 177.0 125.0 37.1 12 (36.4)
Irritative voiding symptoms 21 139.5 125.0 25.6 8 (38.1)
Urolithiasis 13 122.6 75.0 44.7 4 (30.8)
Urinary tract infection 23 103.8 82.0 24.6 4 (17.4)
Group III: Bladder tumors 92 210.2 145.8 25.9 45 (48.9)
Primary tumors 68 232.0 154.0 33.7 34 (50.0)
Recurrent tumors 24 148.4 128.7 24.8 11 (45.8)
By stage
pTa 60 175.0 120.8 24.9 26 (43.3)
pT1–4 18 257.2 116.7 87.1 8 (44.4)
CIS 14 300.3 275.0 69.6 11 (78.6)
By grade
Low 54 192.6 116.7 42.0 22 (40.7)
High 38 286.5 204.0 52.5 23 (60.5)
Group IV: Follow-up (under surveillance after TUR) 59 162.5 91.7 31.6 17 (28.8)
Table 2. Heparanase Levels in the Urine of Bladder Cancer Patients.
No. of Patients Mean (pg/ml) Median (pg/ml) SEM P
Healthy control participant 41 61.6 32.5 10.5
Active disease 92 210.2 145.8 25.9
< .0001*
= .022†
NED 59 162.5 91.7 31.6 = .0013
*Relative to healthy controls.
†Relative to NED.
Figure 2. Receiver operating characteristic (ROC) curve of urinary
heparanase. An ROC curve was extracted using all patients
(groups I, II, III, and IV). The curve provides an optimization of
the sensitivity–specificity ratio of the assay. The area under the
curve is 0.6 ± 0.04, yielding an optimal heparanase cutoff value
of 154 pg/ml.
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TUR (Table 2). This notion is in agreement with recent findings,
demonstrating reduced plasma heparanase levels following anticancer
treatment [28].
The low percentage of false-positive cases (4.6%; Table 3) en-
courages heparanase employment for bladder cancer diagnosis, with
the following limitations: 1) Overall, only 48.9% of bladder cancer
patients were above the calculated cutoff value (45 of 92), leaving ap-
proximately 50% of the cases (47 of 92) undetected. This relatively
high level of false-negative value decreases dramatically as the tumor
progresses to CIS, where the false-negative value drops to 21.4%
(Table 1). 2) Elevation of urinary heparanase was also noted in non-
cancerous disorders. Thus, a positive result in the ELISA method re-
flects a pathologic disorder, but not necessarily cancer, and requires
determination of additional cellular and molecular markers for accu-
rate diagnosis. A combination of methods has become, in fact, the
established means for bladder cancer diagnosis, as no single assay is
sufficiently sensitive and accurate [37]. For example, microscopic he-
maturia can be fairly accurate, yet up to 25% of patients with bladder
cancer will not develop hematuria [38]. Cytology and cytoscopy are
widely used for bladder cancer diagnosis and staging, but flat lesions,
in particular CIS, and low-grade or Ta superficial bladder cancer cases
are more difficult to detect [37]. False-negative cytoscopy was esti-
mated at the range of 10% to 40% [38], thus urging the develop-
ment of additional diagnostic tools. A number of urinary markers for
bladder cancer have been investigated in recent years, and several,
such as bladder tumor antigen, NMP-22, and fibrinogen degenera-
tive product, have been approved by the Food and Drug Administra-
tion [33,37,38]. Neither of these markers is, however, sufficiently
accurate by itself. For example, NMP-22 has a false-positive rate of
25% or even higher (33%–50%) among patients with urolithiasis
and inflammation [33]. Furthermore, NMP-22 has a false-negative
rate of 45% to 55% at the initial diagnosis [39,40], although sensi-
tivity increases with tumor size, grade, and stage [33], very similar to
the performance of heparanase (Figure 1, B and C; Table 1). In con-
trast, the combination of NMP-22 and cytoscopy increases the over-
all sensitivity to 99% [40], clearly illustrating the need for a
combination of methods for accurate diagnosis. An optimal combi-
nation of urine markers has not been investigated, probably due to
the high cost of such a study. NMP-22 also has a lower sensitivity for
detecting recurrent tumors compared to primary tumors because re-
current tumors are often smaller [33]. The feasibility of the hepara-
nase ELISA method for bladder cancer surveillance is yet to be
resolved and is currently being investigated.
Taken together, bladder tumors have a strong tendency for recur-
rence, resulting in high overall disease prevalence. Early detection of
high-grade lesions and surveillance following TUR is required to im-
prove patient’s prognosis, an objective that largely depends on a sen-
sitive and reliable diagnosis. Our results suggest that urine heparanase
levels, combined with other diagnostic means, may prove beneficial
for monitoring bladder cancer progression and thereby improving pa-
tients’ outcome.
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